Apeloa Opens 17,000 Sq. Ft. CDMO R&D Center in Billerica

• Apeloa Pharma Solutions inaugurates its 17,000-square-foot R&D centre in Billerica, Massachusetts.

• The facility focuses on preclinical chemistry, scale-up production, and new drug development platforms.

Apeloa Pharma Solutions, has recently launched its first R&D centre in the United States. The 17,000-square-foot facility in Billerica, Massachusetts, was inaugurated on 10 September with a ribbon-cutting ceremony attended by company leaders, local government representatives, and nearly 100 pharmaceutical and biotech industry professionals.

The new lab will offer services such as preclinical chemistry route exploration, kilogram-scale production, and platform development for PROTAC, antibody-drug conjugates (ADCs), and peptide synthesis. A Boston-based team of experienced scientists will lead operations, aiming to address the dynamic chemistry needs of drug development.

The centre is designed to enhance Apeloa’s contract manufacturing capabilities by providing advanced R&D solutions for customers. Located in a region known as a hub for scientific innovation, the facility strengthens the company’s global presence. The event concluded with tours of the lab and a reception celebrating the establishment of the company’s first US site.